{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T10:00:21Z","timestamp":1769853621343,"version":"3.49.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.cca.2025.120730","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T09:04:32Z","timestamp":1763629472000},"page":"120730","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical laboratory testing of blood from patients presenting to the emergency department with acute bleeding due to factor Xa inhibitors: An unmet medical need"],"prefix":"10.1016","volume":"580","author":[{"given":"Alan H.B.","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Franklin","family":"Peacock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2025.120730_bb0005","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa0809329","article-title":"Estimation of the warfarin dose with clinical and pharmacogenetic data","volume":"360","author":"The International Warfarin Pharmacogenetics Consortium","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cca.2025.120730_bb0010","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s11239-019-01915-9","article-title":"Assessing patient prferences for switching from warfarin to direct oral anticoagulants","volume":"48","author":"Wright","year":"2019","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.cca.2025.120730_bb0015","first-page":"437","article-title":"International council for standardization in haematology (ICSH) recommendation for laboratory measurement of direct oral anticoagulants","volume":"119","author":"Gosselin","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cca.2025.120730_bb0020","first-page":"1","article-title":"Evaluation of the DOAC-stop procedure by LC-MS\/MS assays for determining the residual activity of dabigatran, rivaroxaban,and apixaban","volume":"25","author":"Slavik","year":"2019","journal-title":"Clin Appl Thromb\/Hemostas"},{"key":"10.1016\/j.cca.2025.120730_bb0025","first-page":"445","article-title":"Laboratory monitoring of direct oral anticoagulants (DOACs)","volume":"9","author":"Dunois","year":"2021","journal-title":"Biomed"},{"key":"10.1016\/j.cca.2025.120730_bb0030","article-title":"Goreta SS, et al chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivfaroxaban and apixaban: possibilities and limitations","volume":"30","author":"Margetic","year":"2020","journal-title":"BIoochem Med (Zagreg)"},{"key":"10.1016\/j.cca.2025.120730_bb0035","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.thromres.2023.03.010","article-title":"Bleeding related to oral anticoagulants: Trends in US emergency department visits, 2016\u20132020","volume":"225","author":"Geller","year":"2023","journal-title":"Thromb Res"},{"key":"10.1016\/j.cca.2025.120730_bb0040","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13049-025-01334-1","article-title":"Prothombin complex concentration for resversal of oral anticoagulants in patients with oral anticoagulation-related critical bleeding: a systematic review of randomized clinical trials","volume":"33","author":"Ovesen","year":"2025","journal-title":"Scand J Trauma Resuse Emerg Med"},{"key":"10.1016\/j.cca.2025.120730_bb0045","article-title":"Thrombolysis for ischaemic stroke despite direct oral anticoagulation","volume":"0","author":"Purrucker","year":"2023","journal-title":"Strok Vascul Neurol"},{"key":"10.1016\/j.cca.2025.120730_bb0050","doi-asserted-by":"crossref","first-page":"502","DOI":"10.5603\/CJ.a2023.0043","article-title":"Andexanet alfa \u2013 recommendations for clinical use. Multidisciplinary experts\u2019 standpoint","volume":"30","author":"Kubica","year":"2023","journal-title":"Cardiol J"},{"key":"10.1016\/j.cca.2025.120730_bb0055","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1161\/STROKEAHA.120.031108","article-title":"Economic evaluation of Andexanet vsersus prothrombin complex concentrate for reversal of factor X-a associated intracranial hemorrhage","volume":"52","author":"Micieli","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.cca.2025.120730_bb0060","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11239-019-01973-z","article-title":"Cost comparison of Andexanet versus prothrombin complex concentrations for direct factor Xa inhibitor reversal after hemorrhage","volume":"49","author":"Frontera","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.cca.2025.120730_bb0065","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s11239-020-02143-2","article-title":"Point-of-care testing of coagulation in patients treated with edoxaban","volume":"50","author":"Hartig","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.cca.2025.120730_bb0070","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1055\/s-0042-1750327","article-title":"Performance of a qualitative point-of-care strip test to detect DOAC exposure at the emergency department: a cohort-type cross-sectional diagnostic accuracy study","volume":"122","author":"Merrelaar","year":"2022","journal-title":"Haemost"},{"key":"10.1016\/j.cca.2025.120730_bb0075","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.991675","article-title":"The impact of direct oral anticoagulants on viscoelastic testing \u2013 a systematic review","volume":"9","author":"Sahli","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.cca.2025.120730_bb0080","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1055\/a-2306-0804","article-title":"Clinical pathways and outcomes of Andexanet alfa administration for the reversal of critical bleeding in patients on oral direct factor Xa inhibitors","volume":"8","author":"Goldin","year":"2024","journal-title":"TH Open"},{"key":"10.1016\/j.cca.2025.120730_bb0085","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1161\/STROKEAHA.123.043033","article-title":"Code ICH: a call to action","volume":"56","author":"Li","year":"2024","journal-title":"Stroke"},{"key":"10.1016\/j.cca.2025.120730_bb0090","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1182\/hematology.2024000666","article-title":"DOACs: role of anti-Xa and drug level monitoring","volume":"1","author":"Mithoowani","year":"2024","journal-title":"Hematol"},{"key":"10.1016\/j.cca.2025.120730_bb0095","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/jth.13227","article-title":"When and how to use antidotes for the reversal of direct anticoagulants: guidance from the SSC of the iSTH","volume":"14","author":"Levy","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.cca.2025.120730_bb0100","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/2396987317699144","article-title":"Wahlgren N for the ESO-KSU session participants. Recommendations from the ESO-Karolinska stroke update conference, Stockholm 13-15 November 2016","volume":"2","author":"Ahmed","year":"2017","journal-title":"E Strok J"},{"key":"10.1016\/j.cca.2025.120730_bb0105","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/ene.13582","article-title":"Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants","volume":"25","author":"Touze","year":"2018","journal-title":"E J Neurol"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898125006096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898125006096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T17:57:55Z","timestamp":1769795875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898125006096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":21,"alternative-id":["S0009898125006096"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2025.120730","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical laboratory testing of blood from patients presenting to the emergency department with acute bleeding due to factor Xa inhibitors: An unmet medical need","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2025.120730","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"120730"}}